NCT05712460View on ClinicalTrials.gov

A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

April 28, 2023

Study Completion Date

April 28, 2023

Conditions

Respiratory Syncytial Viruses

Interventions

DRUG

sisunatovir

Sisunatovir is an orally administered RSV F-protein inhibitor being developed to target viral-host cell fusion for the treatment of adult and pediatric patients with RSV

DRUG

Placebo

Placebo for sisunatovir

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels